NEW YORK -- Drug developer Bristol-Myers Squibb Co. said today that its third-quarter profit more than doubled on a surge in sales of its blood thinner Plavix, and raised its outlook for adjusted 2007 earnings.
The company earned $858 million, or 43 cents per share, compared with a profit of $338 million, or 17 cents a share, during the same period a year ago. Excluding one-time items, the company said it earned 38 cents a share in the latest quarter.
Revenue rose 22 percent to $5.05 billion from $4.15 billion.
Analysts polled by Thomson Financial expected profit of 37 cents per share on revenue of $5.02 billion.
Plavix sales doubled to $1.25 billion, offsetting falling sales of cholesterol drug Pravachol and making up the bulk of the company's pharmaceutical sales.
The company said it would take a fourth-quarter charge to account for the buyout of Adnexus, which will drive 2007 earnings to a range of $1.28 to $1.33 per share. Excluding one-time items, Bristol-Myers lifted its profit projections to a range of $1.42 to $1.47 per share from $1.35 to $1.45 previously.
Analysts are expecting profit of $1.44 per share for the full year.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.